Key Points
- Insider sale: Joseph Lyssikatos sold 20,000 Enliven (ELVN) shares on Jan 20 at an average price of $26.75 for $535,000, trimming his stake by 2.61% to 745,188 shares; the trade was reported on an SEC Form 4.
- Shares opened at $27.03 (down about 0.6%), trading near a 52-week high of $29.98 with a market cap of roughly $1.6 billion and 50-/200-day moving averages around $20.32.
- Wall Street's consensus is a “Moderate Buy” with an average target of $41 (four Buy, one Sell), and institutional investors own about 95% of the stock.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 1,230 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $26.75, for a total transaction of $32,902.50. Following the completion of the sale, the director directly owned 23,877 shares in the company, valued at approximately $638,709.75. This trade represents a 4.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Enliven Therapeutics Stock Down 0.6%
Enliven Therapeutics stock opened at $27.03 on Friday. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $29.98. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -14.69 and a beta of 0.41. The firm has a 50-day moving average price of $20.36 and a two-hundred day moving average price of $20.32.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.11. Research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Hedge Funds Weigh In On Enliven Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Enliven Therapeutics by 30.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,818 shares of the company's stock worth $508,000 after purchasing an additional 5,754 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Enliven Therapeutics in the third quarter worth about $334,000. Vestal Point Capital LP increased its position in shares of Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company's stock worth $23,745,000 after acquiring an additional 910,000 shares in the last quarter. Polar Capital Holdings Plc lifted its position in shares of Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company's stock valued at $63,355,000 after acquiring an additional 44,713 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Enliven Therapeutics by 19.8% in the 3rd quarter. Millennium Management LLC now owns 381,405 shares of the company's stock worth $7,807,000 after purchasing an additional 62,956 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently weighed in on ELVN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Wednesday. Wall Street Zen raised Enliven Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $41.00.
View Our Latest Stock Analysis on ELVN
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
